S$3.56 (up 6.59%): T14.SI Tianjin Pharma (SES) 16 Feb 2026: volume rise, yield

The T14.SI stock closed at S$3.56 on 16 Feb 2026 after a 6.59% gain on heavy trading volume of 210,100 shares. This move pushed the share price above its 50-day average of S$3.28 and kept it well above the 200-day average of S$2.85. Investors reacted to a recently published annual dividend notice and solid underlying metrics, turning T14.SI into a high-volume mover on the Singapore Exchange (SES). We break down the drivers, valuation, analyst-grade and short-term outlook.

## Price action and high-volume flow for T14.SI stock

T14.SI stock rose S$0.22 to S$3.56, a 6.59% daily increase on 16 Feb 2026. The session range was S$3.43–S$3.57 and trading volume hit 210,100, above the 3-month average of 175,222.

Relative volume was 2.33, signalling stronger than normal participation and confirming the high-volume mover status. The one-day jump follows a year-to-date gain of 3.30% and a one-year gain of 57.80%, showing both short-term momentum and longer-term strength.

## Fundamental snapshot: earnings, yield and valuation

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SI) reports EPS S$0.67 and trades at a PE of 5.13, well below the Healthcare sector average PE of 22.17. The company lists on SES and shows a market capitalisation near S$5.17B.

Recent news lists an annual dividend of S$0.67 per share with a reported yield around 20.02% (ex-dividend 30 Jan 2026) source. The high yield helps explain the heavy volume today, but yields of this size deserve scrutiny against payout sustainability.

## Technical signals and short-term momentum for T14.SI stock

Momentum indicators are constructive. The RSI sits at 61.31, above neutral but below overbought levels. MACD histogram is positive and ADX is 24.93, showing a trending market.

Price sits near the Bollinger upper band (upper S$3.52; middle S$3.23; lower S$2.95). Short-term traders can view support near S$3.28 (50-day MA) and stronger support near S$2.85 (200-day MA).

## Meyka AI grade and valuation context

Meyka AI rates T14.SI with a score out of 100: 74.05 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects strong profitability metrics, low leverage, and a robust dividend signal.

Key ratios: current ratio 2.81, ROE 42.25%, dividend yield (market) roughly 20.02%, and debt-to-equity 0.00 (near-zero). These figures support a defensive, dividend-focused valuation case but also call for careful review of dividend sustainability.

## Risks, catalysts and sector context for T14.SI stock

Primary risks include dividend sustainability, inventory cycle length (days of inventory 239.31), and slower revenue growth last year at -11.14%. The company also has longer receivables (DSO 111.40) which can pressure cash conversion.

Catalysts include dividend clarity from management, stronger hospital and retail sales in China, and sector tailwinds for drug manufacturers. Healthcare peers on the SES trade at higher PE multiples, which frames T14.SI as a value/dividend play within the sector.

## Trading note and short-term outlook

Traders should note the relative volume 2.33 and the open at S$3.44 today, which shows buyer interest above prior close S$3.34. Short-term support is S$3.28, resistance near S$3.57 and broader resistance near the Bollinger upper band at S$3.52.

For position sizing, combine dividend intent with technical stops under the 50-day MA. Monitor corporate filings for dividend confirmation and any change to payout policy.

Final Thoughts

T14.SI stock closed S$3.56 on 16 Feb 2026 after heavy volume and a 6.59% daily gain. Fundamentals show a low PE of 5.13, strong ROE at 42.25%, and a high market dividend yield reported at about 20.02%. These figures explain active buying but also raise questions on payout durability. Meyka AI’s forecast model projects a one-year price of S$3.97, implying an 11.45% upside from today’s price. Forecasts are model-based projections and not guarantees. Short-term traders can use the 50-day MA S$3.28 as a tactical support level. Long-term investors should verify dividend coverage and watch operating cash flow trends before increasing exposure. For more detailed tick-level updates see the T14.SI page on Meyka AI T14.SI summary on Meyka and the dividend notice source.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.